114-07-8 Usage
Originator
Ilotycin,Dista,US,1952
Indications
Erythromycin is an antibiotic in the macrolide family
that also has promotility effects because
it is a motilin agonist.
Manufacturing Process
An inoculum broth is prepared having the following composition: 32 pounds
starch; 32 pounds soybean meal; 10 pounds corn steep solids; 10 pounds
sodium chloride; 6 pounds calcium carbonate; and 250 gallons water.The broth is placed in an iron tank of 350 gallon capacity and is sterilized by
heating it under pressure at a temperature of about 120°C for 30 minutes.
The sterilized broth is cooled and inoculated aseptically with spores of
Streptomyces erythreus, NRRL 2338. The organism is grown in the broth at
about 26°C for a period of 45 hours. During the growth period the broth isstirred and aerated with sterile air in the amount of about 0.5 volume of air
per volume of culture broth per minute.In a 1,600-gallon iron tank is placed a fermentation broth having the following
composition: 153 pounds starch; 153 pounds soybean meal; 51 pounds corn
steep solids; 33 pounds calcium carbonate; 51 pounds sodium chloride; and
1,200 gallons water.The culture broth is sterilized by heating it under pressure at about 120°C for
about 30 minutes. The broth is cooled and the above inoculant culture is
added aseptically. The organism is grown in the broth for 4 days at a
temperature of 26°C. During the growth period the broth is stirred and sterile
air is blown through the broth at a rate of about 0.5 volume of air per volume
of broth per minute. At the end of the growth period the broth shows an
antibiotic activity equivalent to about 150 mcg of erythromycin per ml of
broth.The culture broth (about 1,100 gallons in volume) is adjusted to pH 9.5 with
40% sodium hydroxide solution and is filtered to remove the mycelium, the
filtration being assisted by use of 3% of Hyflo Super-Cel, a filter aid, (sold by
Johns-Manville Company). The clear filtrate is extracted with amyl acetate in a
Podbielniak extractor using a ratio of 1 volume of amyl acetate to 6 volumes
of clarified broth. The amyl acetate extract is in turn extracted batchwise with
water brought to about pH 5 by the addition of sulfuric acid. Two extractions
are carried out, the first with ? volume and the second with ? volume of
water adjusted to pH 5 with sulfuric acid. The aqueous extracts are combined
and adjusted to pH 8.0 with sodium hydroxide solution.The alkaline solution is concentrated in vacuo to a volume of about 30 gallons
and the solution is then adjusted to pH 9.5 by the addition of aqueous sodium
hydroxide and is allowed to stand. Erythromycin separates as a crystalline
material. The crystals are filtered off, the mother liquor is adjusted to about
pH 8 by the addition of dilute sulfuric acid and is concentrated in vacuo to a
volume of about 30 gallons. The solution is adjusted to about pH 9.5 and
allowed to stand, whereupon an additional amount of erythromycin separates
in crystalline form. The total amount of erythromycin obtained is about 256
grams. The erythromycin is purified by several recrystallizations from aqueous
acetone (2:1 mixture), according to US Patent 2,653,899.
Therapeutic Function
Antibacterial
Antimicrobial activity
Gram-positive rods, including Clostridium spp. (MIC50 0.1–1 mg/L), C. diphtheriae (MIC50 0.1–1 mg/L), L. monocytogenes (MIC50 0.1–0.3 mg/L) and Bacillus anthracis (MIC50 0.5–1.0 mg/L), are generally susceptible. Most strains of M. scrofulaceum and M. kansasii are susceptible (MIC50 0.5–2 mg/L), but M. intracellulare is often and M. fortuitum regularly resistant. Nocardia isolates are resistant. H. ducreyi, B. pertussis (MIC50 0.03–0.25 mg/L), some Brucella, Flavobacterium, Legionella (MIC50 0.1–0.5 mg/L) and Pasteurella spp. are susceptible. H. pylori (MIC 0.06–0.25 mg/L) and C. jejuni are usually susceptible, but C. coli may be resistant. Most anaerobic bacteria, including Actinomyces and Arachnia spp., are susceptible or moderately so, but B. fragilis and Fusobacterium spp. are resistant. T. pallidum and Borrelia spp. are susceptible, as are Chlamydia spp. (MIC ≤0.25 mg/L), M. pneumoniae and Rickettsia spp. M. hominis and Ureaplasma spp. are resistant. Enterobacteriaceae are usually resistant. Activity rises with increasing pH up to 8.5. Incubation in 5–6% CO2 raises the MIC for H. influenzae from 0.5–8 to 4–32 mg/L; MICs for Str. pneumoniae and Str. pyogenes also rise steeply. Activity is predominantly bacteristatic.
Acquired resistance
In Europe, the USA and other countries the incidence of resistance in Str. pneumoniae ranges from 5% to over 60%. In Str. pneumoniae strains resistant or intermediately susceptible to penicillin G, resistance rates above 80% have been reported. Increasing rates of resistance in clinical isolates of Str. pyogenes have also been reported, threatening its use as an alternative to penicillin G in allergic patients. Lower rates of resistance have been reported in other bacterial species, including methicillin-resistant Staph. aureus, coagulase-negative staphylococci, Str. agalactiae, Lancefield group C and G streptococci, viridans group streptococci, H. pylori, T. pallidum, C. diphtheriae and N. gonorrhoeae.
Pharmaceutical Applications
A natural antibiotic produced as a complex of six components (A–F) by Saccharopolyspora erythraea. Only erythromycin A has been developed for clinical use. It is available in a large number of forms for oral administration: the base compound (enteric- or film-coated to prevent destruction by gastric acidity); 2′-propionate and 2′-ethylsuccinate esters; a stearate salt; estolate and acistrate salts of 2′-esters. The 2′-esters and their salts have improved pharmacokinetic and pharmaceutical properties and are less bitter than erythromycin. It is also formulated as the lactobionate and gluceptate forparenteral use.
Biological Activity
Erythromycin is the principal one in antimicrobial drugs. Although available as the parent entity, semisynthetic derivatives have proved to be clinically superior to the natural cogener. Like the tetracyclines, synthetic transformations in the macrolide series have not significantly altered their antibacterial spectra, but have improved the pharmacodynamic properties. For example, the propionate ester of erythromycin lauryl sulfate (erythromycin estolate) has shown greater acid stability than the unesterified parent substance. Although the estolate appears in the blood somewhat more slowly, the peak serum levels reached are higher and persist longer than other forms of the drug. However, cholestatic hepatitis may occasionally follow administration of the estolate and, for that reason, the stearate is often preferred. Erythromycin is effective against Group A and other nonenterococcal streptococci, Corynebacterium diphtheriae, Legionella pneumophila, Chlamydia trachomatis, Mycoplasma pneumoniae, and Flavobacterium. Because of the extensive use of erythromycin in hospitals, a number of Staph. aureus strains have become highly resistant to the drug. For this reason, erythromycin has been used in combination with chloramphenicol. This combination is also used in the treatment of severe sepsis when etiology is unknown and patient is allergic to penicillin.
Biological Activity
The oral bioavailability of erythromycin base is poor and is highly
variable because of inactivation by gastric acidity. Formulations with an acid-resistant coating have therefore been
developed, as well as esters with improved oral bioavailability. Stearate
is hydrolyzed in the intestine, whereas ethylsuccinate is absorbed both
as the free base (55%) and the ester (45%) formulations. These are best
absorbed in the fasting state. Estolate absorption is not affected by food;
20–30% of the serum concentration corresponds to the active form and
70–80% to the ester prodrug.
Serum protein binding varies between 40% and 90%. Alcohol can cause
a moderate reduction in the absorption of erythromycin succinate.
Biochem/physiol Actions
Mode of Action: Erythromycin acts by inhibiting elongation at the transpeptidation step, specifically aminoacyl translocation from the A-site to P-site by binding to the 50s subunit of the bacterial 70s rRNA complex.Antimicrobial Spectrum: This product acts against both gram-negative and gram-positive bacteria.
Mechanism of action
Macrolides are inhibitors of protein synthesis at the ribosomes. They impair the elongation cycle of the
peptidyl chain by specifically binding to the 50S subunit of the
ribosome. Specificity toward prokaryotes relies upon the absence of
50S ribosomes in eukaryotes. The main interaction site is located at
the central loop of the domain V of the 23S rRNA, at the vicinity
of the peptidyl transferase center. The macrolide binding site is located
at the entrance of the exit tunnel used by the nascent peptide chain to
escape from the ribosome, at the place where the central loop of
domain V interacts with proteins L4 and L22 and with the loop of
754 Macrolides and Ketolides
hairpin 35 in domain II of rRNA.
Interaction occurs via the formation of hydrogen-bonds between the
reactive groups (2u-OH) of the desosamine sugar and the lactone ring and adenine residue 2058. This explains why
mutation or methylation in position 2058 as well as mutations in proteins
L4 and L22 confer resistance to macrolides. The binding site of macrolides on the ribosome overlaps that of chloramphenicol or lincosamides
such as clindamycin, explaining pharmacologic
antagonism between these antibiotic classes as well as cross-resistance.
Pharmacology
Erythromycin inhibits bacterial protein synthesis by reversibly binding with their 50
S ribosomal subunit, thus blocking the formation of new peptide bonds. Erythromycin is
classified as a bacteriostatic antibiotic.
However, it can also exhibit a bactericidal effect against a few types of microbes at certain concentrations.
Bacterial resistance to erythromycin can originate by two possible mechanisms: the
inability of reaching the cell membrane, which is particularly relevant in the case of the
microorganisms Enterobacteriaceae, or in the case of the presence of a methylated alanine
in the 23 S ribosomal RNA of the 50 S subunit, which lowers the affinity of erythromycin to it.
Erythromycin acts on Gram-positive (staphylococci both produced and not produced by
penicillinase, streptococci, pneumococci, clostridia) and a few Gram-negative microorganisms (gonococci, brucelli, hemophile and whooping cough bacilli, legionelli), mycoplasma,
chlamydia, spirochaeta, and Rickettsia. Colon and blue-pus bacilli, as well as the bacilli
shigella, salmonella, and others are resistant to erythromycin.
Pharmacokinetics
absorption and metabolism The acid lability of erythromycin base necessitates administration in a form giving protection from gastric acid. In acid media it is rapidly degraded (10% loss of activity at pH 2 in less than 4 s) by intramolecular dehydrogenation to a hemiketal and hence to anhydroerythromycin A, neither of which exerts antibacterial activity. Delayed and incomplete absorption is obtained from coated tablets and there is important inter- and intra-individual variation, adequate levels not being attained at all in a few subjects. Food delays absorption of erythromycin base. After 500 mg of the 2′-ethylsuccinyl ester, mean peak plasma levels at 1–2 h were 1.5 mg/L. In subjects given 1 g of the 2′-ethylsuccinate every 12 h for seven doses, the mean plasma concentration 1 h after the last dose was around 1.4 mg/L. Intra- and inter-subject variation and delayed and erratic absorption in the presence of food have not yet been eliminated by new formulations. Improved 500 mg preparations of erythromycin stearate are claimed to produce peak plasma levels of 0.9–2.4 mg/L that are little affected by the presence of food. 2′-Esters of erythromycin are partially hydrolyzed to erythromycin： 2′-acetyl erythromycin is hydrolyzed more rapidly than the 2′-propionyl ester, but more slowly than the 2′-ethylsuccinate.The stoichiometric mixture with stearate does not adequately protect erythromycin from acid degradation. After an oral dose of erythromycin stearate, equivalent concentrations of erythromycin and its main degradation product, anhydroerythromycin, could be detected.Doses of 10 mg/kg produced mean peak plasma concentrations around 1.8 mg/L in infants weighing 1.5–2 kg and 1.2 mg/L in those weighing 2–2.5 kg. In infants less than 4 months old, doses of 10 mg/kg of the 2′-ethylsuccinate every 6 h produced steady state plasma levels of around 1.3 mg/L. The apparent elimination half-life was 2.5 h. In children given 12.5 mg/kg of erythromycin 2′-ethylsuccinate every 6 h, the concentration in the plasma 2 h after the fourth dose was around 0.5–2.5 mg/L.DistributionVery low levels are obtained in cerebrospinal fluid (CSF), even in the presence of meningeal inflammation, and after parenteral administration. Levels of 0.1 mg/L in aqueous humor were found when the serum level was 0.36 mg/L, but there was no penetration into the vitreous. In children with otitis media given 12.5 mg/kg of erythromycin 2′- ethylsuccinate every 6 h, concentrations in middle ear exudate were 0.25–1 mg/L. In patients with chronic serous otitis media given 12.5 mg/kg up to a maximum of the equivalent of 500 mg, none was detected in middle ear fluid, but on continued treatment levels up to 1.2 mg/L have been described.Penetration also occurs into peritoneal and pleural exudates. Mean concentrations of 2.6 mg/L have been found in sputum in patients receiving 1 g of erythromycin lactobionate intravenously every 12 h and 0.2–2 mg/L in those receiving an oral stearate formulation. Levels in prostatic fluid are about 40% of those in the plasma. Salivary levels of around 4 mg/L were found in subjects receiving doses of 0.5 g every 8 h at 5 h after a dose, when the plasma concentration was around 5.5 mg/L. Intracellular:extracellular ratios of 4–18 have been found in polymorphonuclear neutrophils.Fetal tissue levels are considerably higher after multiple doses： when the mean peak maternal serum level was 4.94 (0.66–8) mg/L, the mean fetal blood concentration was 0.06 (0–0.12) mg/L. Concentrations were more than 0.3 mg/L in amniotic fluid and most other fetal tissues, but the concentrations were variable and unmeasurable in some. Erythromycin appears to be concentrated by fetal liver.excretionErythromycin is excreted both in urine and in the bile but only a fraction of the dose can be accounted for in this way. Only about 2.5% of an oral dose or 15% of an intravenous dose is recovered unchanged in the urine. It is not removed to any significant extent by peritoneal dialysis or hemodialysis. Reported changes in apparent elimination half-life in renal impairment may be related to the saturable nature of protein binding. Fairly high concentrations (50–250 mg/L) are found in the bile. In cirrhotic patients receiving 500 mg of the base, peak plasma levels were higher and earlier than in healthy volunteers (2.0 and 1.5 mg/L
at 4.6 and 6.3 h, respectively). The apparent elimination half-life was 6.6 h. It is possible that the smaller excretion of the 2′-propionyl ester in the bile in comparison to the base accounts in part for its better-maintained serum levels. There is some enterohepatic recycling, but some of the administered dose is lost in the feces, producing concentrations of around 0.5 mg/g.
Clinical Use
Erythromycin is used (offlabel
indication) to accelerate gastric emptying in diabetic
gastroparesis and postoperative gastroparesis.
Tachyphylaxis will occur, so it cannot be used uninterruptedly
for long periods.
Side effects
Oral administration, especially of large doses, commonly causes epigastric distress, nausea and vomiting, which may be severe. Solutions are very irritant: intravenous infusions almost invariably produce thrombophlebitis. Cholestatic hepatitis occurs rarely. Transient auditory disturbances have been described after intravenous administration of the lactobionate salt, and occasionally in patients with renal and hepatic impairment in whom oral dosage has produced high plasma levels. Sensorineural hearing impairment can occur and, although this is usually a reversible effect which occurs at high dosage, can be permanent. Prolongation of the apparent elimination half-life of carbamazepine, due to inhibition of its conversion to the epoxide, usually results in central nervous system (CNS) disturbances. Nightmares are troublesome in some patients. Allergic effects occur in about 0.5% of patients.The estolate is particularly prone to give rise to liver abnormalities, consisting of upper abdominal pain, fever, hepatic enlargement, a raised serum bilirubin, pale stools and dark urine and eosinophilia. The condition is rare and usually seen 10–20 days after the initiation of treatment, with complete recovery on stopping the drug. Recurrence of symptoms can be induced by giving the estolate but not the base or stearate. There is evidence that erythromycin estolate is more toxic to isolated liver cells than is the 2′-propionate or the base, and it is suggested that the essential molecular feature responsible for toxicity is the propionyl–ester linkage. The relative frequency of the reaction, its rapidity of onset (within hours) after second courses of the drug, evidence of hypersensitivity and the histological appearance suggest a mixture of hepatic cholestasis, liver cell necrosis and hypersensitivity. Abnormal liver function tests in patients receiving the estolate must be interpreted with caution, since increased levels of transaminases is often the only abnormality and some metabolites of the estolate can interfere with the measurement commonly used. Elevated
levels of transaminases return to normal after cessation of treatment. Serum bilirubin is generally unchanged in these patients, but γ-glutamyl transpeptidase may also be affected.
Safety Profile
Poison by intravenous
and intramuscular routes. Moderately toxic by ingestion, intraperitoneal, and
subcutaneous routes. An experimental
teratogen. Other experimental reproductive
effects. Mutation data reported. When
heated to decomposition it emits toxic
fumes of NOx.
Synthesis
Erythromycin, (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2,6-dideoxy-3-Cmethyl-3-O-methyl-α-L-ribo-hexopyranosyl)-oxy]-14-ethyl-7,12,13-trihydroxy-
3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy
]oxacyclotetradecan-2,10-dione (32.2.1), is more specifically called erythromycin A. It was
first isolated in 1952 from the culture liquid of microorganisms of the type Streptomyces
erytherus. Minor amounts of erythromycin B and C were also found in the culture fluid.
Erythromycin B differs from A in that a hydrogen atom is located at position 12 in the place
of a hydroxyl group, while erythromycin C differs from A in that the residue of a different carbohydrate, micarose (2-6-di-deoxy-3-C-methyl-L-ribohexose), is bound to the macrocycle in
position 3 in the place of cladinose (4-methoxy-2,4-dimethyl-tetrahydropyran-3,6-diol).
Erythromycin A is produced only microbiologically using active strains of microorganisms of the type Saccharopolospora erythraea.
Veterinary Drugs and Treatments
Erythromycin is approved for use to treat infections caused by susceptible
organisms
in swine, sheep, and cattle. It is often employed
when an animal is hypersensitive to penicillins or if other antibiotics
are ineffective against a certain organism.
Erythromycin, at present, is considered to be one of the treatments
of choice (with rifampin) for the treatment of C. (Rhodococcus) equi
infections in foals. Erythromycin estolate and microencapsulated
base appear to be the most efficacious forms of the drug in foals due
to better absorption and less frequent adverse effects.
Erythromycin may be used as a prokinetic agent to increase gastric
emptying in dogs and cats. It may also be beneficial in treating
reflux esophagitis.
Drug interactions
Potentially hazardous interactions with other drugsAminophylline and theophylline: inhibits
aminophylline and theophylline metabolism; if
erythromycin given orally decreased erythromycin
concentration.Anti-arrhythmics: increased risk of ventricular
arrhythmias with IV erythromycin and amiodarone
- avoid; increased toxicity with disopyramide;
increased risk of ventricular arrhythmias with
dronedarone - avoid.Antibacterials: increased risk of ventricular
arrhythmias with moxifloxacin and IV erythromycin
- avoid; possibly increased rifabutin concentration -
reduce rifabutin dose; concentration of bedaquiline
possibly increased - avoid if for more than 14 days;
possibly increased risk of ventricular arrhythmias
with delamanid; avoid with fidaxomicin.Anticoagulants: enhanced effect of coumarins;
concentration of edoxaban increased - reduce
edoxaban dose.Antidepressants: avoid concomitant use with
reboxetine; avoid IV erythromycin with citalopram
and escitalopram, risk of ventricular arrhythmias;
risk of ventricular arrhythmias with venlafaxine -
avoid.Antiepileptics: increased carbamazepine
concentration and possibly valproate.Antifungals: avoid with fluconazole.Antihistamines: possibly increases loratadine
concentration; inhibits mizolastine metabolism -
avoid concomitant use; concentration of rupatadine
increased.Antimalarials: avoid with artemether/lumefantrine;
increased risk of ventricular arrhythmias with
piperaquine with artenimol - avoid.Antimuscarinics: avoid concomitant use with
tolterodine.Antipsychotics: increased risk of ventricular
arrhythmias with sulpiride and zuclopenthixol
and IV erythromycin avoid; possibly increases
clozapine concentration leading to increased risk
of convulsions; possibly increased lurasidone
concentration; possibly increased risk of ventricular
arrhythmias with amisulpride, droperidol and
pimozide - avoid; possibly increased quetiapine
concentration Antivirals: concentration of both drugs increased
with telaprevir and simeprevir, avoid with simeprevir;
concentration increased by ritonavir; avoid with rilpivirine, concentration increased; increased risk of
ventricular arrhythmias with saquinavir - avoid. Anxiolytics and hypnotics: inhibits midazolam
and zopiclone metabolism; increases buspirone
concentration.Atomoxetine: increased risk of ventricular
arrhythmias with parenteral erythromycin.Avanafil: concentration of avanafil increased, max
dose 100 mg every 48 hours.Calcium-channel blockers: possibly inhibit
metabolism of calcium channel blockers; avoid with
lercanidipine.Ciclosporin: markedly elevated ciclosporin blood
levels - decreased levels on withdrawing drug.
Monitor blood levels of ciclosporin carefully and
adjust dose promptly as necessary.Cilostazol: concentration of cilostazol increased,
reduce cilostazol to 50 mg twice daily.Clopidogrel: possibly reduced antiplatelet effectColchicine: increased risk of colchicine toxicity -
suspend or reduce dose of colchicine, avoid in hepatic
or renal impairment.Cytotoxics: possibly increased afatinib concentration,
separate administration by 6-12 hours;
concentration of axitinib increased - reduce axitinib
dose; concentration of bosutinib possibly increased
- avoid or reduce dose of bosutinib; concentration
of cabozantinib, dasatinib and ibrutinib and
possibly olaparib increased - avoid with dasatinib,
reduce dose of ibrutinib, avoid or reduce dose of
olaparib; concentration of everolimus possibly
increased; increased risk of ventricular arrhythmias
with IV erythromycin and vandetanib - avoid;
possible interaction with docetaxel; increased risk
of ventricular arrhythmias with arsenic trioxide;
increases vinblastine toxicity - avoid.Diuretics: increased eplerenone concentration -
reduce eplerenone dose.Domperidone: possible increased risk of ventricular
arrhythmias - avoid.Ergot alkaloids: increase risk of ergotism - avoid
concomitant use.5HT1
agonists: increased eletriptan concentration -
avoid concomitant use.Ivabradine: increased risk of ventricular arrhythmias
- avoid concomitant use.Ivacaftor: concentration of ivacaftor possibly
increasedLipid-lowering drugs: possibly increased myopathy
with atorvastatin; concentration of pravastatin
increased; concentration of rosuvastatin reduced;
avoid concomitant use with simvastatin.1
;
concentration of lomitapide possibly increased -
avoid.Pentamidine: increased risk of ventricular
arrhythmias with IV erythromycin.Sildenafil: concentration of sildenafil increased -
reduce initial dose for ED or reduce frequency to
twice daily for PAH.Sirolimus: concentration of both drugs increased.Tacrolimus: markedly elevated tacrolimus blood
levels - decreased levels on withdrawing drug.
Monitor blood levels of tacrolimus carefully and
adjust dose promptly as necessaryTicagrelor: concentration of ticagrelor possibly
increased.
Metabolism
Erythromycin is partly metabolised in the liver
by the cytochrome P450 isoenzyme CYP3A4 via
N-demethylation to inactive, unidentified metabolites.
It is excreted in high concentrations in the bile and
undergoes intestinal reabsorption. About 2-5% of an
oral dose is excreted unchanged in the urine and as much
as 12-15% of an intravenous dose may be excreted
unchanged by the urinary route.
Purification Methods
It recrystallises from H2O to form hydrated crystals which melt at ca 135-140o, resolidifies and melts again at 190-193o. The melting point after drying at 56o/8mm is that of the anhydrous material and is at 137-140o. Its solubility in H2O is ~2mg/mL. The hydrochloride has m 170o, 173o (from aqueous EtOH, EtOH/Et2O). [Flynn et al. J Am Chem Soc 76 3121 1954, constitution: Wiley et al. J Am Chem Soc 79 6062 1957]. [Beilstein 18/10 V 398.]
Dosage forms
1 g/day in divided doses.
Check Digit Verification of cas no
The CAS Registry Mumber 114-07-8 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 1,1 and 4 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 114-07:
(5*1)+(4*1)+(3*4)+(2*0)+(1*7)=28
28 % 10 = 8
So 114-07-8 is a valid CAS Registry Number.
InChI:InChI=1/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21?,22-,23+,24+,25-,26+,28-,29?,30?,31+,32?,34?,35-,36-,37-/m1/s1
114-07-8Relevant articles and documents
Method for preparing high-purity erythrocin A
-
Paragraph 0074; 0075; 0076; 0078; 0079; 0080; 0081, (2016/12/22)
The invention provides a method for preparing high-purity erythrocin A. According to the method, the high-purity erythrocin A is prepared by alkali transduction on erythromycin thiocyanate and aqueous-phase recrystallization, and the problem of viscosity in a preparation process of erythrocin A in the prior art is effectively solved. The method provided by the invention has a stable process, is easy to operate, and can prepare products with the erythrocin A as high as 96% or more in content; the erythrocin A can be used as a reference substance of the erythrocin A; besides, in the alkali transduction process, the price of dichloromethane used as a solvent is only about half the price of acetone adopted as a solvent in a traditional process, therefore, the production cost is greatly lowered, and the method has a great application prospect.
A NOVEL PROCESS OF LIBERATION OF ERYTHROMYCIN AND PREPARATION OF ITS SALTS
-
Page/Page column 12, (2014/09/29)
The present invention relates to a novel process for the liberation of Erythromycin from Erythromycin salts such as Erythromycin thiocyanate using water as a solvent in presence of a base. Erythromycin obtained by process of the present invention has purity of more than 95%. The present invention further relates to a novel process for the preparation of Erythromycin Stearate by reacting Erythromycin or its salts with stearic acid in presence of water.
Benzoyl Peroxide Composition, Methods for Making Same, and Pharmaceutical or Cosmetic Formulations Comprising Same, and Uses Thereof
-
, (2012/03/27)
The present invention relates to the preparation of compositions comprising benzoyl peroxide, with or without other additional active ingredients. The process involves introducing benzoyl peroxide, along with any other active ingredients present, into a fatty substance that contains and protects the ingredients that would otherwise be unstable when in contact with one another. The composition is designed to allow all ingredients to become available for skin contact or skin absorption when the fatty substance softens and/or melts as the composition is applied to the skin. The benzoyl peroxide may be pre-micronized to a particle distribution size of about d90 of 0.1 to 150 microns, preferably d90 of 10 to 15 microns. Further, pharmaceutical or cosmetic ingredients may be contained within the fatty substances, with or without, benzoyl peroxide therein or may be present outside of the fatty substance but elsewhere within formulated pharmaceutical or cosmetic products using the active ingredients protected by the fatty substance. These compositions are useful in aqueous-based formulations to treat diseases by topical, transdermal and/or subcutaneous administration.
CRYSTALLIZING METHOD OF ERYTHROMYCIN
-
Page/Page column 3, (2011/07/30)
The present invention provides an erythromycin crystallizing method, which comprises using dichloromethane containing solvent as a preparation solvent, and the dichloromethane solution of erythromycin received was gradiently cooled from high temperature down to low temperature, and thus making erythromycin crystallize. According to the method of the present invention, the content of erythromycin A is high, the content of erythromycin A in the erythromycin crystalline is more than 94.5% (HPLC detection method), the content of dichloromethane in the erythromycin crystalline is less than 600 ppm, the content of water in the erythromycin crystalline is less than 2.5%, the microbiological titre of the erythromycin crystalline is more than 940μ/mg.
METHOD OF PREPARING CLARITHROMYCIN
-
Page/Page column 3, (2010/12/29)
This invention discloses a method of manufacturing clarithromycin, where an erythromycin A 9-oxime thiocyanate salt is used directly to perform an etherification reaction, and then successively silanizattion, methylattion and hydrolysis reactions are sequentially conducted. It is a new process with simple process with a high yield, low cost, less pollution, high quality and is suitable for commercial manufacturing.
Process for the preparation of clarithromycin
-
Page/Page column 4-6, (2009/04/24)
The present invention includes a process involving a one-pot reaction for preparing erythromycin 9-oxime salt comprising: (a) reacting erythromycin thiocyanate with an ammonium source to obtain erythromycin free base; (b) oximating the C-9 carbonyl of the erythromycin free base by reacting the erythromycin free base with triethylamine and hydroxyl amine hydrochloride to form erythromycin oxime; and (c) reacting the erythromycin oxime obtained in step (b) with an ammonium source to obtain the erythromycin 9-oxime salt. The present invention is also drawn to a one-pot reaction for preparing clarithromycin starting with the one-pot reaction for preparing erythromycin 9-oxime salt, further comprising after step (c): (d) silylating the hydroxy groups at the oxime group, and the 2′ and 4″ positions of the erythromycin 9-oxime salt to obtain a silylated derivative; (e) methylating the hydroxy group at the 6 position of the silylated derivative using at least one methylating agent in the presence of at least one inorganic base to obtain SMOP, wherein SMOP is 6-O-methyl-2′,4″-bis(trimethylsilyl)-erythromycin A 9-O-(2-methoxyprop-2-yl)oxime; and (f) converting the SMOP into clarithromycin using at least one deoximating agent in the presence of aqueous ethanol.
A PROCESS FOR PREPARING 6,9-IMINO ETHER
-
Page/Page column 11, (2008/06/13)
A process for preparing 6,9-Imino ether from Erythromycin thiocyanate without isolating Erythromycin base and Erythromycin oxime and Beckmann's rearrangement of erythromycin oxime is carried in the presence biphasic solvent system comprising methylene chloride and water in the presence of triethylamine along with sodium bicarbonate to obtain 87-96 % pure 6,9-Imino ether. Further the 6,9-Imino ether is hydrogenated to 9-Deoxo-9a-aza-9a-homoerythromycin A followed by reductive methylation to obtain Azithromycin dihydrate.
Amido macrolides
-
, (2008/06/13)
Various macrolide compounds such as those having the following formulas are provided where the variables have the values provided herein.
From (E)- and (Z)-ketoximes to N-sulfenylimines, ketimines or ketones at will. Application to erythromycin derivatives
Esteban, Jorge,Costa, Anna M.,Urpí, Fèlix,Vilarrasa, Jaume
, p. 5563 - 5567 (2007/10/03)
Reactions of (E)- and (Z)-ketoximes with trialkylphosphines and diphenyl disulfide (PhSSPh) have been compared to gain insight into the mechanisms involved and their potential applications. N-Sulfenylimine isomers and ketimines have been spectroscopically characterised. Both the E and Z isomers of erythromycin A oxime, when treated with Bu3P and PhSSPh (1:4:8 ratio), give the same N-phenylsulfenyl ketimine (of configuration E) as the major compound, whereas with Bu3P or Me3P and PySeSePy (1:8:4 ratio) afford the imine in good yield. Clarithromycin oxime behaves similarly.
Derivatives of erythromycin, clarithromycin, roxithromycin or azithromycin with antibiotic and mucolytic activity
-
, (2008/06/13)
A pharmaceutical with an enhanced pharmaceutical profile comprises a mucolytic and an antibiotic in which the mucolytic is present in an amount of greater than one molar equivalent of the antibiotic. The antibiotic may be selected from Erythromycin, Roxithromycin, Clarithromycin, Azithromycin, Dirithromycin; and pharmaceutically acceptable salts or esters thereof. The mucolytic is a mucolytically active thiol, especially N-acetylcysteine, mercaptoethanesulfonic acid, tiopronin or methylcysteine. The adducts can be isolated via a simple and efficient process.
